Smoldering multiple myeloma: Natural history and recognition of an evolving type

British Journal of Haematology

Volumn 123, Issue 4, 2003, Pages 631-636

  Rosinol L ^a   Blade J ^a,b   Esteve, J ^a   Aymerich, M ^a   Rozman, M ^a   Montoto, S ^a   Gine E ^a   Nadal, E ^a   Filella, X ^a   Queralt, R ^a   Carrio A ^a   Montserrat, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Chemotherapy; Malignant transformation; Multiple myeloma; Prognosis; Smoldering

Indexed keywords

IMMUNOGLOBULIN A; M PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOLDERING MULTIPLE MYELOMA; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW EXAMINATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PLASMA CELLS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0345392556     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04654.x     Document Type: Article

References (14)

1. Alexanian, R., Barlogie, B. & Dixon, D. (1988) Prognosis of asymptomatic multiple myeloma. Archives Internal Medicine, 148, 1963-1965.
2. Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hematopoietic stem cell transplantation. British Journal of Haematology, 102, 1115-1123.
3. Dimopoulos, M., Moulopoulos, L., Smith, T., Delasalle, K. & Alexanian, R. (1993) Risk of disease progression in asymptomatic multipe myeloma. American Journal of Medicine, 94, 57-61.
4. Dimopoulos, M., Monopoulos, L., Maniatis, A. & Alexanian, R. (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 96, 2037-2044.
5. Facon, T., Menard, J.F., Michaux, J.L., Euller-Ziegher, L., Bernard, J.F., Grosbois, B., Daragon, A., Azais, I., Courouble, Y., Kaplan, G., Laporte, J.P., De Gramont, A., Duclos, B., Leonard, A., Mineur, P., Delannoy, A., Jouet, J.P., Bauters, F. & Monconduit, M. (1995) Prognostic factors in low tumor mass asymptomatic multiple myeloma: a report on 91 patients. American Journal of Hematology, 48, 71-75.
6. Hjorth, M., Hellquist, L., Homberg, E., Magnusson, B., Rödjer, S. & Westin, J. (1993) Initial versus deferred Melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study. European Journal of Haematology, 50, 95-102.
7. Kaplan, E.L. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal American Statistically Association, 53, 457-481.
8. Kyle, R.A. & Greipp, P.R. (1980) Smoldering multiple myeloma. New England Journal of Medicine, 302, 1347-1349.
9. Kyle, R., Thernau, T., Rajkumar, V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. III (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564-569.
10. Montoto, S., Bladé, J. & Montserrat, E. (2002) Monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 2087-2088 (Letter to the Editor).
11. Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6.633 patients from 27 randomized trials. Journal Clinical of Oncology, 16, 3832-3842.
12. Peto, R. & Pike, M.C. (1973) Conservation of the aproximation (O-E)/ E in the logrank test for survival data or tumor incidence data. Biometrics, 29, 579-584.
13. Weber, D., Dimopoulos, M., Monopoulos, L., Delasalle, K., Smith, T. & Alexanian, R. (1997) Prognostic features of asymptomatic multiple myeloma. British Journal of Haematology, 97, 810-814.
14. Wisloff, F., Andersen, P. & Andersson, T.R., (1991) Incidence and follow-up of asymptomatic multiple myeloma. European Journal of Haematology, 47, 338-341.